TCM Treatment for AECOPD Patients with Drug-resistant Lung Infections

doi:10.12114/j.issn.1007-9572.2020.00.306

Abstract

Abstract: Bacteria are the most common pathogens of pulmonary infections.Due to recently extensive abuse of antibiotics，the rate of drug-resistant bacteria in pulmonary infections has been rising，and new drug-resistant strains have been emerging，which becomes a difficult problem in medical and health care.Drug-resistant bacterial infection is frequently seen in patients with acute exacerbation of chronic obstructive pulmonary disease（AECOPD），often leading to repeated attacks and hospitalization.The disease belongs to the category of "pulmonary distention" and " asthma syndrome" in traditional Chinese medicine（TCM），and its onset is closely related to dysfunctional lung and spleen according to visceral manifestation theory and five-element theory.In this paper，an in-depth analysis is performed on the therapeutic thoughts on TCM treatment of a case of AECOPD with drug-resistant lung infections.

Key words: Pulmonary disease, chronic obstructive；Bacterial infections；Drug-resistant bacteria；TCM therapy

摘要： 细菌是肺部感染最常见的致病菌，由于近年来抗生素的广泛滥用，导致肺部感染的细菌耐药率不断攀升，且新的耐药菌株不断出现，是当今医疗卫生领域的难题。慢性阻塞性肺疾病急性加重（AECOPD）是临床的常见疾病，耐药细菌感染在AECOPD患者中十分常见，常导致患者病情反复发作和住院。本病属中医学“肺胀”“喘证”等范畴，中医学脏象学说理论和五行学说理论认为，肺脾两脏功能失调与本病关系密切，本文以中医药临床治疗AECOPD合并耐药细菌感染为例，分析探讨肺部耐药细菌感染的中医治疗思路。

关键词: 肺疾病, 慢性阻塞性；细菌感染；耐药细菌；中医治疗

LENG Jianchun. TCM Treatment for AECOPD Patients with Drug-resistant Lung Infections　[J]. Chinese General Practice, 2020, 23(27): 3457-3459. DOI: 10.12114/j.issn.1007-9572.2020.00.306.
冷建春. 慢性阻塞性肺疾病急性加重患者肺部耐药细菌感染的中医药治疗探讨[J]. 中国全科医学, 2020, 23(27): 3457-3459. DOI: 10.12114/j.issn.1007-9572.2020.00.306.

References

［1］程知音，吴斌.肺部感染病原体的构成谱及耐药现状［J］．国际呼吸杂志，2011，31（22）：1751-1754.
CHENG Z Y，WU B.Antimicrobiai resistance and composition of algogen pathogeny in pulmonary infection［J］．International Journal of Respiration，2011，31（22）：1751-1754.
［2］王贵花.慢性阻塞性肺疾病急性加重期病原菌检测及其耐药性分析［J］．检验医学与临床，2014，11（8）：1052-1053．DOI:10.3969/j.issn.1672-9455.2014.08.020.
WANG G H.Distribution and drug resistance of pathogenic bacteria in patients with acute exacerbation chronic obstructive pulmonary disease［J］．Laboratory Medicine and Clinic，2014，11（8）：1052-1053．DOI:10.3969/j.issn.1672-9455.2014.08.020.
［3］郭丹，李琼，王翟，等．老年慢阻肺患者合并肺部感染的病原体分析［J］．航空航天医学杂志，2016，27（7）：869-870．DOI:10.3969/j.issn.2095-1434.2016.07.033.
［4］周仲瑛.中医内科学［M］．北京：中国中医药出版社，2003.
［5］刘洪霞，金克峙.预防医院耐药菌感染——2014年美国［J］．上海预防医学，2017，29（2）：163-167．DOI：10.19428/j.cnki.sjpm.2017.02.023.
［6］杜鹃，谢峻，郑颖城，等．《抗生素耐药:全球监测报告2014》解读与反思［J］．华南国防医学杂志，2014，28（8）：814-817．DOI:10.3969/j.issn.1009-2595.2014.08.028.
DU J，XIE J，ZHENG Y C，et al．Interspersion and learning of Antimicrobial Resistance：Global Report on Surveillance 2014 from WHO［J］．Military Medical Journal of South China，2014，28（8）：814-817．DOI:10.3969/j.issn.1009-2595.2014.08.028.
［7］夏照帆，吕开阳，汤陈琪，等．我国细菌耐药问题的现状和防控策略［J］．中国工程科学，2017，19（2）：106-111．DOI:10.15302/J-SSCAE-2017.02.018.
XIA Z F，LYU K Y，TANG C Q，et al．The status and control strategy of bacterial resistance in China［J］．Engineering Sciences，2017，19（2）：106-111．DOI:10.15302/J-SSCAE-2017.02.018.
［8］田磊，陈中举，孙自镛，等．2005—2014年CHINET肠杆菌属细菌耐药性监测［J］．中国感染与化疗杂志，2016，16（3）：275-283．DOI：10.16718/j.1009-7708.2016.03.007.
TIAN L，CHEN Z J，SUN Z Y，et al．Antibiotic resistance profile of Enterobacter in hospitals across China：data from CHINET Antimicrobial Resistance Surveillance Program from 2005 through 2014［J］．Chinese Journal of Infection and Chemotherapy，2016，16（3）：275-283．DOI：10.16718/j.1009-7708.2016.03.007.
［9］国家卫生计生委合理用药专家委员会，全国细菌耐药监测网.2015年全国细菌耐药监测报告［J］．中国执业药师，2016，13（3）：3-8.
Expert Committee on Rational Drug Use of National Health and Health Commission，China Bacterial Resistance Monitoring Network System.National bacterial resistance monitoring report in 2015［J］． China Licensed Pharmacist，2016，13（3）：3-8.
［10］王传清，王爱敏，张泓，等．2009年中国CHINET链球菌属细菌耐药性监测［J］．中国感染与化疗杂志，2010，10（6）：426-429．DOI:10.16718/j.1009-7708.2010.06.006.
WANG C Q，WANG A M，ZHANG H，et al．CHINET 2009 surveillance of antibiotic resistance in Streptococcus spp in China［J］．Chinese Journal of Infection and Chemotherapy，2010，10（6）：426-429．DOI:10.16718/j.1009-7708.2010.06.006.
［11］国家卫生计生委，国家发展改革委，教育部，科技部，工业和信息化部，财政部，国土资源部，环境保护部，农业部，文化部，新闻出版广电总局，食品药品监管总局，国家中医药管理局，中央军委后勤保障部卫生局.关于印发遏制细菌耐药国家行动计划（2016—2020年）的通知［EB/OL］．（2016-08-25）［2019-06-25］.http://www.gov.cn/xinwen/2016-08/25/content_5102348.htm.
［12］李新，王金良.细菌耐药性机制的研究进展［J］．国外医学临床生物化学与检验学分册，2001（5）:261-263.
［13］郭玉红，吴彦青，刘清泉.耐药菌下呼吸道感染的中医药优化治疗研究进展［J］．世界中医药，2016，11（10）：1937-1939，1944．DOI:10.3969/j.issn.1673-7202.2016.10.001.
GUO Y H，WU Y Q，LIU Q Q.Research progress of traditional Chinese medicine treatment on drug-resistant bacterial lower respiratory tract infection［J］．World Chinese Medicine，2016，11（10）：1937-1939，1944．DOI:10.3969/j.issn.1673-7202.2016.10.001.
［14］林玉洁，李建军，黄启辉.中医对老年耐药细菌性肺炎的认识［J］．广州医药，2010，41（6）：44-47．DOI:10.3969/j.issn.1000-8535.2010.06.023.
［15］焦扬，杨效华，刘娟.活血解毒法治疗耐药菌致细菌性肺炎57例［J］．北京中医药大学学报，2001，24（5）：53-54．DOI:10.3321/j.issn:1006-2157.2001.05.017.
JIAO Y，YANG X H，LIU J.Treatment of 57 cases of bacterial pneumonia caused by drug-fast bacteria by th e therapy for activating blood circulation and dispelling toxins［J］．Journal of Beijing University of Traditional Chinese Medicine，2001，24（5）：53-54．DOI:10.3321/j.issn:1006-2157.2001.05.017.
［16］孙志欣，陈莉，李锐，等．参苓白术散对老年社区获得性肺炎肺脾气虚证患者血清炎症因子及免疫功能的影响［J］．中国实验方剂学杂志，2017，23（21）：161-165．DOI:10.13422/j.cnki.syfjx.2017210161.
SUN Z X，CHEN L，LI R，et al．Effect of shenling Baishu San combined with antibiotics on serum inflammatory factors，immune function in senile community-acquired pneumonia with syndrome of qi deficiency of both lung and spleen［J］．Chinese Journal of Experimental Traditional Medical Formulae，2017，23（21）：161-165．DOI:10.13422/j.cnki.syfjx.2017210161.

[1]	LIU Jian, ZHANG Tianyi, AILIZHATI ·Aizezi, CHANG Ruijing, ZHANG Jianli, WANG Wan, JIANG Peng. Cardiopulmonary Physiology Effects of Wearing a Surgical Mask Versus an N95 Respirator in Patients with COPD during Walking: a Randomized Crossover Controlled Trial [J]. Chinese General Practice, 2023, 26(24): 3028-3032.
[2]	SHEN Junxi, ZHU Xing, CHEN Yunzhi, LI Wen. Novel Developments in Lung and Gut Microbiota and Their Cross-talk with the Development of Chronic Obstructive Pulmonary Disease [J]. Chinese General Practice, 2023, 26(20): 2548-2554.
[3]	LIANG Zhenyu, WANG Fengyan, CHEN Zizheng, CHEN Rongchang. Updated Key Points Interpretation of Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2023 Report) [J]. Chinese General Practice, 2023, 26(11): 1287-1298.
[4]	WANG Tong, QUAN Haishan, TIAN Bowen, LI Ying, CUI Qianqian, LIU Yao, ZHU Huahua. Fatigue in Chronic Obstructive Pulmonary Disease: a Scoping Review [J]. Chinese General Practice, 2023, 26(07): 893-902.
[5]	LIU Jiancai, ZHENG Hanyin, PAN Hui, YE Linglan, LI Chuanfen. Perceptions of Chronic Obstructive Pulmonary Disease among Chronic Disease Managers in Primary Care in Rural Areas [J]. Chinese General Practice, 2023, 26(07): 877-885.
[6]	WANG Yide, LI Zheng, LI Fengsen. Role of Endocrine Function of Adipose Tissue in the Development of Chronic Obstructive Pulmonary Disease: a Review of Recent Advances [J]. Chinese General Practice, 2023, 26(06): 754-759.
[7]	SHI Weijuan, WANG Fengyan, YANG Yuqiong, XIE Qingxiu, LI Yuqi, LI Shiyue, CHEN Rongchang, ZHANG Dongying, ZHENG Jinping, LIANG Zhenyu. Impact of COVID-19 Pandemic on the Frequency of Acute Exacerbations of Chronic Obstructive Pulmonary Disease [J]. Chinese General Practice, 2023, 26(05): 550-556.
[8]	HU Yiqing, FANG Jiwei, LIU Huanbing. Attaching Importance to the Application of Lung Function Examination Technology in Grassroots Medical and Health Institutions——Expert Answers to Key Questions [J]. Chinese General Practice, 2023, 26(05): 532-540.
[9]	BAI Yahu, GAO Shenghan, JI Siyu, SHANG Jinyu, DONG Yanchun, NING Kang. Pre-COPD: a New Advance in COPD [J]. Chinese General Practice, 2023, 26(03): 268-273.
[10]	GUO Dongwei, ZHANG Pengfei, REN Mingjun, LIAO Lijun, HUANG Ruyan, LUO Xiangrong. Mechanistic of Ginkgo Biloba Extract in the Prevention and Treatment of COPD: Regulating Autophagy in Alveolar Macrophages via PI3K/Akt/mTOR Signaling Pathways [J]. Chinese General Practice, 2023, 26(03): 293-303.
[11]	FANG Ziyan, LI Xueer, YANG Xuening, LIU Jing, YANG Congyan, ZHANG Feng, AKIMANA Sandra, WANG Yan, ZHANG Jing. Effect of Fatigue on the Possibility of Acute Exacerbation in COPD: a Prospective Cohort Study [J]. Chinese General Practice, 2023, 26(03): 287-292.
[12]	HUANG Tao, LUO Na, LUO Song, XU Qin. Clinical Application of a Novel Noninvasive Positive Pressure Ventilation Face Mask with Two Channels and Constant Leakage for Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Carbon Dioxide Retention [J]. Chinese General Practice, 2023, 26(03): 343-347.
[13]	WU Jiankang, CHEN Yan. Interpretation of the Lancet Commission on Towards the Elimination of Chronic Obstructive Pulmonary Disease: New Definition and Recommendations for Clinical Management of Chronic Obstructive Pulmonary Disease [J]. Chinese General Practice, 2023, 26(02): 127-133.
[14]	LIU Yue, YUAN Yuan. Diagnostic Accuracy of Screening Tools for Chronic Obstructive Pulmonary Disease: a Network Meta-analysis [J]. Chinese General Practice, 2022, 25(35): 4443-4452.
[15]	CHANG Chun, SUN Yongchang. Global Strategy for Asthma Management and Prevention: Interpretation of the Updates in 2022 [J]. Chinese General Practice, 2022, 25(35): 4355-4362.